# A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

> **NCT02171780** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 122 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1744 CL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02171780
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2005-07
- **Final completion:** —
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171780, "A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02171780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*